Schizophrenia and Oxidative Stress: Glutamate Cysteine Ligase Modifier as a Susceptibility Gene
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Oxidative stress could be involved in the pathophysiology of schizophrenia, a major psychiatric disorder. Glutathione (GSH), a redox regulator, is decreased in patients' cerebrospinal fluid and prefrontal cortex. The gene of the key GSH-synthesizing enzyme, glutamate cysteine ligase modifier (GCLM) subunit, is strongly associated with schizophrenia in two case-control studies and in one family study. GCLM gene expression is decreased in patients' fibroblasts. Thus, GSH metabolism dysfunction is proposed as one of the vulnerability factors for schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“several divergent genetic (e.g. Gclc, Gclm, Disc1, PRODH, G72, NRG1) (9–17) or external factors (e.g. stress, social isolation, ketamine, neonatal ventral hippocampal lesion) (18–24) collectively lead to redox dysregulation.”
From Prolonged Period of Cortical Plasticity upon Redox Dysregulation in Fast-Spiking Interneurons (2015) · cites this paper as [10]
In the citing paper
“Genetic analysis of single nucleotide polymorphisms in schizophrenia patients demonstrates mutations in the gene encoding GCL, an enzyme that is important for the production of the cellular antioxidant GSH (Tosic et al., 2006).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Tosic et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_5485 · Cited by 10,169
Meister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,680
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297 · cited 1×
“Gheorghita, unpublished data) and, selectively, in GABAparvalbumin immunoreactivity of prefrontal cortex,(21) similar to patients.(38,39) The same rat model presented an impairment in object recognition(18,19) and in integration ofolfactory information,(40) reproducingsomecognitivedeficits of schizophrenia.”
BackgroundDiagnostic Interview for Genetic Studies: Rationale, Unique Features, and Training
Nurnberger, J. I. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110009002 · Cited by 2,053
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J.-J., Griffin, J. L., Wayland, M., Freeman, T., Dudbridge, F., Lilley, K. S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001511 · Cited by 971
Schizophrenia: genes and environment
Tsuang, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00289-9 · Cited by 597
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Research works printed but not linked: 1
- Cabungcal, 2004, Special bias deficit in rats with low glutathione during development: a behaviour model with relevance to schizophrenia, Schizophr Res, 67, 118
Cited by
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
“Genetic polymorphisms of antioxidant enzymes, associated with psychiatric disorders (Akyol et al., 2005; Saadat et al., 2007; Tosic et al., 2006), may have potential in assisting the identification of at-risk individuals.”
BackgroundGawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594
“Others have found that GCL alterations modulate GSH levels (Lavoie et al. 2009), this enzyme’s gene is a potential susceptibility gene in SCZ (Tosic et al. 2006), and its expression is affected by mood-stabilizer treatment (Cui et al. 2007).”
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Rossignol, D. A., & Frye, R. E. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.165 · Cited by 543
Perineuronal nets protect fast-spiking interneurons against oxidative stress
Cabungcal, J.-H., Steullet, P., Morishita, H., Kraftsik, R., Cuenod, M., Hensch, T. K., & Do, K. Q. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300454110 · Cited by 512
“Therefore, redox dysregulation via impaired GSH synthesis (21, 22) or abnormal function of proteins encoded by other susceptibility genes [i.”
BackgroundSelf-citationBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Oxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 472
Mitochondrial Dysfunction and Psychiatric Disorders
Rezin, G. T., Amboni, G., Zugno, A. I., Quevedo, J., & Streck, E. L. (2009) · Neurochemical Research · doi:10.1007/s11064-008-9865-8 · Cited by 442
“A recent focus was made on the mutations in the enzyme glutamate cystein ligase modifier that would result in a decreased antioxidant response in patients with this illness. ( 12 )”
BackgroundFranklin, C. C., Backos, D. S., Mohar, I., White, C. C., Forman, H. J., & Kavanagh, T. J. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.009 · Cited by 438
Redox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
“Polymorphisms in the gene of the modifier subunit of this enzyme as well as decreased expression of this gene have been associated with schizophrenia (Do et al, in press; Tosic et al, 2006; Gysin et al, 2007).”
BackgroundSelf-citationSteullet, P., Cabungcal, J.-H., Coyle, J., Didriksen, M., Gill, K., Grace, A. A., Hensch, T. K., LaMantia, A.-S., Lindemann, L., Maynard, T. M., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.47 · Cited by 360
Self-citationImpaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence
Gysin, R., Kraftsik, R., Sandell, J., Bovet, P., Chappuis, C., Conus, P., Deppen, P., Preisig, M., Ruiz, V., Steullet, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706778104 · Cited by 309
Self-citationSteullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262
“polymorphisms and copy number variations in genes related to the GSH metabolism (Gravina et al., 2011; Gysin et al., 2007; Mehta et al., 2013; Rodriguez-Santiago et al., 2010; Tosic et al., 2006).”
Glutathione defense mechanism in liver injury: Insights from animal models
Chen, Y., Dong, H., Thompson, D. C., Shertzer, H. G., Nebert, D. W., & Vasiliou, V. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.008 · Cited by 251
“…risks for certain diseases, including cardiovascular disease (Koide et al. 2003; Nakamura et al. 2002; Nakamura et al. 2003), neurological disorder (Berk et al. 2011; Tosic et al. 2006), pulmonary disease (Bentley et al. 2008; McConnachie et al. 2013) and cancer (Nichenametla et al. 2012).”
BackgroundInterleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia
Behrens, M. M., Ali, S. S., & Dugan, L. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4457-08.2008 · Cited by 241
Oxidative Stress‐Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
Ermakov, E. A., Dmitrieva, E. M., Parshukova, D. A., Kazantseva, D. V., Vasilieva, A. R., & Smirnova, L. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8881770 · Cited by 233
“At the same time, no association with glutathione synthase genes has been observed in Danish and Swiss populations [61].”
BackgroundCabungcal, J.-H., Steullet, P., Kraftsik, R., Cuenod, M., & Do, K. Q. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.020 · Cited by 232
“GSH (25,26) and genetic association between GCLM and schizophrenia (39) have been reported.”
Analysis of whole genome biomarker expression in blood and brain
Rollins, B., Martin, M. V., Morgan, L., & Vawter, M. P. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31062 · Cited by 216
“…have focused on sampling other tissues from living subjects such as nasal biopsy [Wolozin et al., 1993; Vawter et al., 1996; Sawa et al., 1999; McCurdy et al., 2006], skin biopsy [Hagenfeldt et al., 1987; Mukherjee et al., 1994; Catts et al., 2006; Tosic et al., 2006], CSF, urine, serum, and blood.”
BackgroundJuvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
Cabungcal, J.-H., Counotte, D. S., Lewis, E. M., Tejeda, H. A., Piantadosi, P., Pollock, C., Calhoon, G. G., Sullivan, E. M., Presgraves, E., Kil, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.028 · Cited by 204
“This idea is supported by the observation of various polymorphisms in genes encoding glutathione (GSH) synthesis conferring risk for schizophrenia (Gysin et al., 2007; Tosic et al., 2006).”
Steullet, P., Cabungcal, J.-H., Kulak, A., Kraftsik, R., Chen, Y., Dalton, T. P., Cuenod, M., & Do, K. Q. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3857-09.2010 · Cited by 202
“Both catalytic (GCLC) and modifier (GCLM) subunits of the glutamate cysteine ligase (GCL), the rate-limiting enzyme of GSH synthesis, have been associated with the illness (Tosic et al., 2006; Gysin et al., 2007).”
BackgroundSelf-citationMatsuzawa, D., Obata, T., Shirayama, Y., Nonaka, H., Kanazawa, Y., Yoshitome, E., Takanashi, J., Matsuda, T., Shimizu, E., Ikehira, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001944 · Cited by 201
“Subsequently, they reported the GCLM gene as a susceptibility gene for schizophrenia in Swiss and Danish populations [9,15].”
BackgroundMeta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
“Synthesis of GSH, its expression and levels are governed by polymorphism in genes for the glutamate cysteine ligase modifier subunit([47]) and the catalytic subunit for glutamate cysteine ligase,([48]) which are linked to a genetic predisposition for schizophrenia.”
BackgroundMitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders
Kim, Y., Vadodaria, K. C., Lenkei, Z., Kato, T., Gage, F. H., Marchetto, M. C., & Santos, R. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2018.7606 · Cited by 187
Glutathione: a novel treatment target in psychiatry
Berk, M., Ng, F., Dean, O., Dodd, S., & Bush, A. I. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.001 · Cited by 183
McConnachie, L. A., Mohar, I., Hudson, F. N., Ware, C. B., Ladiges, W. C., Fernandez, C., Chatterton-Kirchmeier, S., White, C. C., Pierce, R. H., & Kavanagh, T. J. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm165 · Cited by 183
“…and GCLM are associated with a number of pathologies including chronic beryllium disease, type-I diabetes, cystic fibrosis lung disease, myocardial infarction, and schizophrenia (Bekris et al., 2006, 2007; Koide et al., 2003; McKone et al., 2006; Nakamura et al., 2002, 2003; Tosic et al., 2006).”
BackgroundInflammation in schizophrenia: A question of balance
Leza, J. C., García-Bueno, B., Bioque, M., Arango, C., Parellada, M., Do, K., O’Donnell, P., & Bernardo, M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.014 · Cited by 182
Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia
Maas, D. A., Vallès, A., & Martens, G. J. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.138 · Cited by 181
Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk
Barron, H., Hafizi, S., Andreazza, A., & Mizrahi, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030651 · Cited by 174
“For instance, familial variations in a subunit of GCL, the enzyme responsible for GSH synthesis may increase the risk of schizophrenia up to four-fold [81].”
BackgroundA meta-analysis of oxidative stress markers in schizophrenia
Zhang, M., Zhao, Z., He, L., & Wan, C. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-0013-8 · Cited by 173
Clozapine as a Model for Antipsychotic Development
Nucifora, F. C., Mihaljevic, M., Lee, B. J., & Sawa, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0552-9 · Cited by 173
The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170
“While PNNs were first identified in the late 1800s, much of our current knowledge about PNN structure and function can be attributed to a renewed interest in PNNs almost a Abbreviations: AD, Alzheimer’s disease; ADAMTs, a disintegrin and metalloproteinase with thrombospondin motif; chABC, chondroitinase ABC; CNS, cent…”
BackgroundRaffa, M., Atig, F., Mhalla, A., Kerkeni, A., & Mechri, A. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-124 · Cited by 167
“Furthermore, increased risk of schizophrenia is associated with polymorphisms of genes associated with GSH synthesis [29,30].”
BackgroundPowell, S. B., Sejnowski, T. J., & Behrens, M. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.049 · Cited by 164
Enhanced Carbonyl Stress in a Subpopulation of Schizophrenia
Arai, M., Yuzawa, H., Nohara, I., Ohnishi, T., Obata, N., Iwayama, Y., Haga, S., Toyota, T., Ujike, H., Arai, M., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.62 · Cited by 163
“Biochemical and pharmacological studies using human samples and animal models suggest that oxidative/carbonyl stress contributes to the pathophysiology of schizophrenia.(3-6) Oxidative stress is a central mediator of advanced glycation end product (AGE) formation, and pyridoxamine (vitamin B6, biosynthesized from pyri…”
BackgroundRae, C. D., & Williams, S. R. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2016.12.022 · Cited by 164
Conus, P., Seidman, L. J., Fournier, M., Xin, L., Cleusix, M., Baumann, P. S., Ferrari, C., Cousins, A., Alameda, L., Gholam-Rezaee, M., et al. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx093 · Cited by 162
Self-citationBehrens, M. M., & Sejnowski, T. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 162
Da Silveira Paulsen, B., De Moraes Maciel, R., Galina, A., Da Silveira, M. S., Souza, C. D. S., Drummond, H., Pozzatto, E. N., Junior, H. S., Chicaybam, L., Massuda, R., et al. (2012) · Cell Transplantation · doi:10.3727/096368911x600957 · Cited by 162
Implications for reactive oxygen species in schizophrenia pathogenesis
Koga, M., Serritella, A. V., Sawa, A., & Sedlak, T. W. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.022 · Cited by 159
Davis, J., Moylan, S., Harvey, B. H., Maes, M. H. J., & Berk, M. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414533012 · Cited by 154
“Variance in the glutamate-cysteine ligase regulatory subunit (GCLM) gene, leading to impaired production of glutathione, is a proposed risk factor for schizophrenia (Tosic et al., 2006).”
BackgroundCuénod, M., Steullet, P., Cabungcal, J.-H., Dwir, D., Khadimallah, I., Klauser, P., Conus, P., & Kim, Q. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01374-w · Cited by 137
“They include the catalytic (GCLC) [28] and modulatory (GCLM) [29] subunits of glutamate-cysteine ligase (rate-limiting synthesizing enzyme of GSH), glutathione-S-transferase [30, 31], superoxide dismutase-1 [32], nitric oxide synthase [33, 34].”
BackgroundSelf-citationNeurobiology of Schizophrenia Spectrum Disorders: The Role of Oxidative Stress
Wood, S. J., Yücel, M., Pantelis, C., & Berk, M. (2009) · Annals of the Academy of Medicine, Singapore · doi:10.47102/annals-acadmedsg.v38n5p396 · Cited by 128
das Neves Duarte, J. M., Kulak, A., Gholam-Razaee, M. M., Cuenod, M., Gruetter, R., & Do, K. Q. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.035 · Cited by 124
“Furthermore, the two genes coding for the key GSH-synthesizing enzyme, glutamate-cysteine ligase catalytic (GCLC) and modifier (GCLM) subunits, are associated with schizophrenia (9,10).”
Kulak, A., Steullet, P., Cabungcal, J.-H., Werge, T., Ingason, A., Cuenod, M., & Do, K. Q. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4858 · Cited by 124
“Gene variants of both GCLM and GCLC are associated with greater risk for SZ (50, 118).”
Self-citationLavoie, S., Chen, Y., Dalton, T. P., Gysin, R., Cuénod, M., Steullet, P., & Do, K. Q. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05908.x · Cited by 117
“Gene expression After 18-h treatment, mRNA levels were measured in cultured neurons and astrocytes following a method already described (Tosic et al. 2006).”
BackgroundMethodInfluentialSelf-citationTargeting of NMDA receptors in new treatments for schizophrenia
Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 115
“Furthermore, allelic variants of genes coding for the key GSH synthesizing enzyme, glutathione cysteine ligase modulatory (GCLM) and catalytic (GCLC) subunits are associated with schizophrenia [106,107].”
BackgroundReduced antioxidant defense in early onset first-episode psychosis: a case-control study
Micó, J. A., Rojas-Corrales, M. O., Gibert-Rahola, J., Parellada, M., Moreno, D., Fraguas, D., Graell, M., Gil, J., Irazusta, J., Castro-Fornieles, J., et al. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-26 · Cited by 115
“Anomalies in GSH metabolism were also supported by the low expression of the gene of the key GSH-synthesizing enzyme, glutamate cysteine ligase modifier subunit, in patient fibroblasts [53].”
BackgroundMonin, A., Baumann, P. S., Griffa, A., Xin, L., Mekle, R., Fournier, M., Butticaz, C., Klaey, M., Cabungcal, J. H., Steullet, P., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.88 · Cited by 113
Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation
Wood, S. J., Berger, G. E., Wellard, R. M., Proffitt, T.-M., McConchie, M., Berk, M., McGorry, P. D., & Pantelis, C. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.018 · Cited by 105
Nielsen, D. A., Ji, F., Yuferov, V. P., Ho, A., Chen, A. C. H., Levran, O., Ott, J., & Kreek, M. J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002147 · Cited by 110
Self-citationGenetic Variation in Glutathione-Related Genes and Body Burden of Methylmercury
Engström, K. S., Strömberg, U., Lundh, T., Johansson, I., Vessby, B. O., Hallmans, G., Skerfving, S., & Bröberg, K. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.10804 · Cited by 98
“Indeed, both GSH and GST levels have been shown to decrease with age (Voss and Siems 2006).”
BackgroundSchizophrenia: a disorder of broken brain bioenergetics
Henkel, N., Wu, X., O'Donovan, S. M., Devine, E. A., Jiron, J. M., Rowland, L. M., Sarnyai, Z., Ramsey, A. J., Wen, Z., Hahn, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01494-x · Cited by 108
Reduced antioxidant defense systems in schizophrenia and bipolar I disorder
Raffa, M., Barhoumi, S., Atig, F., Fendri, C., Kerkeni, A., & Mechri, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.013 · Cited by 97
“Genetic polymorphisms of the GSH pathway, including the glutamate-cysteine ligase gene, have been linked to SZ (Tosic et al., 2006) and BD (Fullerton et al., 2010).”
Background(2009) · PubMed · Cited by 95
Prolonged Period of Cortical Plasticity upon Redox Dysregulation in Fast-Spiking Interneurons
Morishita, H., Cabungcal, J.-H., Chen, Y., Do, K. Q., & Hensch, T. K. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.12.026 · Cited by 92
Dean, O. M., van den Buuse, M., Berk, M., Copolov, D. L., Mavros, C., & Bush, A. I. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.027 · Cited by 92
Kulak, A., Cuenod, M., & Do, K. Q. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.10.020 · Cited by 90
Rodríguez-Santiago, B., Brunet, A., Sobrino, B., Serra-Juhé, C., Flores, R., Armengol, L., Vilella, E., Gabau, E., Guitart, M., Guillamat, R., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.53 · Cited by 88
Jiang, Z., Cowell, R. M., & Nakazawa, K. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00116 · Cited by 99
“Using GCLM KO mice, Cabungcal et al. (2013a) demonstrated that impaired synthesis of glutathione delays maturation of PVIs in the anterior cingulate cortex as indicated by reduced PVI numbers, but not calretinin and calbidin positive interneuron numbers, and a reduction in the density of perineuronal nets (PNNs), spec…”
BackgroundMethodInfluentialKhadimallah, I., Jenni, R., Cabungcal, J.-H., Cleusix, M., Fournier, M., Béard, E., Klauser, P., Knebel, J., Murray, M. M., Retsa, C., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01313-9 · Cited by 100
Self-citationCabungcal, J.-H., Preissmann, D., Delseth, C., Cuénod, M., Do, K. Q., & Schenk, F. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.03.001 · Cited by 83
“GCLM gene expression was also decreased in patients’ fibroblasts (Tosic et al., 2006).”
BackgroundSelf-citationCarmeli, C., Knyazeva, M. G., Cuénod, M., & Do, K. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029341 · Cited by 81
“Specifically, (i) GSH levels in the brain and cerebrospinal fluid of patients are decreased [3–5]; (ii) under oxidative stress conditions, activity of the key GSH synthesizing enzyme, glutamate cysteine ligase (GCL), and the GSH levels in patients’ fibroblasts are diminished [6], and (iii) allelic variants of the GCL…”
BackgroundGlutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice
Dean, O., Bush, A. I., Berk, M., Copolov, D. L., & van den Buuse, M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.017 · Cited by 81
Increased systemic oxidatively generated DNA and RNA damage in schizophrenia
Jørgensen, A., Broedbaek, K., Fink‐Jensen, A., Knorr, U., Soendergaard, M. G., Henriksen, T., Weimann, A., Jepsen, P., Lykkesfeldt, J., Poulsen, H. E., et al. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.01.033 · Cited by 85
“…acid damage from oxidation is a ‘‘trait’’ rather than a ‘‘state’’ phenomenon, possibly due to a genetically determined increased oxidative stress, as suggested by others (Tosic et al., 2006), or as a result of more persistent and stable metabolic changes developing early in the disease course.”
BackgroundMagnetic Resonance Spectroscopy Study of the Antioxidant Defense System in Schizophrenia
Matsuzawa, D., & Hashimoto, K. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3453 · Cited by 79
“The activity of GCL, the rate-limiting enzyme for GSH synthesis, as well as the expressions of the catalytic GCL subunit (GCLC) and GCL modifier subunit (GSLM) in cultured skin fibroblasts from schizophrenia patients, were significantly decreased compared with those in control subjects (22, 23, 52).”
Radonjić, N. V., Knežević, I. D., Vilimanovich, U., Kravić-Stevović, T., Marina, L. V., Nikolić, T., Todorović, V., Bumbaširević, V., & Petronijević, N. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.009 · Cited by 75
“Also, genetic association between allelic variations of the GCLM gene and schizophrenia has been shown (To si c et al., 2006).”
NADPH oxidase elevations in pyramidal neurons drive psychosocial stress-induced neuropathology
Schiavone, S., Jaquet, V, Sorce, S., Dubois-Dauphin, M., Hultqvist, M., Bäckdahl, L., Holmdahl, R., Colaianna, M., Cuomo, V, Trabace, L., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.36 · Cited by 75
Barcelos, G. R. M., Grotto, D., de Marco, K. C., Valentini, J., Lengert, A. V. H., de Oliveira, A. Á. S., García, S. C., Braga, G. Ú. L., Engström, K., Cólus, I. M. D. S., et al. (2013) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2013.06.029 · Cited by 84
Rossetti, A. C., Paladini, M. S., Riva, M. A., & Molteni, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107520 · Cited by 77
Duarte, J. M. N., & Xin, L. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2521-z · Cited by 82
Roles of glial cells in schizophrenia: Possible targets for therapeutic approaches
Takahashi, N., & Sakurai, T. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.001 · Cited by 67
The role of lead and cadmium in psychiatry
Orisakwe, O. E. (2014) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.139283 · Cited by 71
Choy, K. H. C., Dean, O., Berk, M., Bush, A. I., & van den Buuse, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.035 · Cited by 62
“This GSH reduction was associated with abnormalities in GSH peroxidase and glutamate cysteine ligase modifier gene (Buckman et al., 1987; Do et al., 2009; Tosic et al., 2006).”
Gysin, R., Kraftsik, R., Boulat, O., Bovet, P., Conus, P., Comte-Krieger, E., Polari, A., Steullet, P., Preisig, M., Teichmann, T., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3463 · Cited by 62
“Human fibroblast cultures were established from skin biopsies, as described (58).”
Self-citationGenetic Association Studies of Antioxidant Pathway Genes and Schizophrenia
Chowdari, K. V., Bamne, M. N., & Nimgaonkar, V. L. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3508 · Cited by 66
“(70) investigated a Danish and a Swiss sample, but did not observe significant association between GSS and SZ.”
BackgroundStojković, T., Radonjić, N. V., Velimirović, M., Jevtić, G., POPOVIC, V. M., Doknić, M., & Petronijević, N. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.013 · Cited by 58
Avshalumov, M. V., Patel, J. C., & Rice, M. E. (2008) · Journal of Neurophysiology · doi:10.1152/jn.90548.2008 · Cited by 54
Is bipolar disorder a mitochondrial disease?
Young, L. T. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0715 · Cited by 50
Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients
Fournier, M., Ferrari, C., Baumann, P. S., Polari, A., Monin, A., Bellier-Teichmann, T., Wulff, J., Pappan, K. L., Cuenod, M., Conus, P., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu053 · Cited by 48
Self-citationSkin Ceramide Alterations in First-Episode Schizophrenia Indicate Abnormal Sphingolipid Metabolism
Smesny, S., Schmelzer, C. E. H., Hinder, A., Köhler, A., Schneider, C., Rudzok, M., Schmidt, U., Milleit, B., Milleit, C., Nenadic, I., et al. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs058 · Cited by 48
MicroRNA schizophrenia: Etiology, biomarkers and therapeutic targets
Zhang, H.-C., Du, Y., Chen, L., Yuan, Z., & Cheng, Y. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105064 · Cited by 50
A comparative 90-day toxicity study of allyl acetate, allyl alcohol and acrolein
Auerbach, S. S., Mahler, J. F., Travlos, G. S., & Irwin, R. D. (2008) · Toxicology · doi:10.1016/j.tox.2008.08.014 · Cited by 47
“Polymorphism in this gene causes decreased expression that is associated with the manifestation of vascular disease and schizophrenia (Nakamura et al 2002; Tosic et al 2006).”
BackgroundWang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
“Polymorphisms in genes coding for enzymes that participate in GSH synthesis have been linked to the risk of schizophrenia (76, 223), and recent results show that genetically compromised GSH synthesis affects the morphological and functional integrity of hippocampal PV + neurons (215).”
Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia
Xia, M., Abazyan, S., Jouroukhin, Y., & Pletnikov, M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.044 · Cited by 46
“…and the dorsolateral prefrontal cortex (PFC) in schizophrenia (Shan et al., 2013; Spangaro et al., 2012); SRR (Morita et al., 2007); and the gene for the astrocytic enzyme that is involved in synthesis of glutathione, a key factor to guard the brain against oxidative stress (Tosic et al., 2006).”
Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
Palaniyappan, L. K., Park, M. T. M., Jeon, P., Limongi, R., Yang, K., Sawa, A., & Théberge, J. (2021) · Antioxidants · doi:10.3390/antiox10111703 · Cited by 60
Oxidative Stress and Emergence of Psychosis
Rambaud, V., Marzo, A., & Chaumette, B. (2022) · Antioxidants · doi:10.3390/antiox11101870 · Cited by 57
Shiwaku, H., & Okazawa, H. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150303002556 · Cited by 46
Phensy, A. J., Duzdabanian, H. E., Brewer, S. M., Panjabi, A., Driskill, C. M., Berz, A., Peng, G., & Kroener, S. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00106 · Cited by 46
“Polymorphisms in genes that code for enzymes involved in the synthesis of GSH have been linked to risk for developing schizophrenia (Tosic et al., 2006; Gysin et al., 2007).”
BackgroundCorcoba, A., Steullet, P., Duarte, J. M. N., van de Looij, Y., Monin, A., Cuénod, M., Gruetter, R., & Kim, Q. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv110 · Cited by 42
“Electrophysiological recordings in the abnormal white matter tracts identified by diffusion tensor imaging were performed to characterize the functional consequences of fractional anisotropy alterations.”
BackgroundSelf-citationRetsa, C., Knebel, J., Geiser, E., Ferrari, C., Jenni, R., Fournier, M., Alameda, L., Baumann, P., Clarke, S., Conus, P., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.008 · Cited by 40
“…in key genes for GSH synthesis have been associated with schizophrenia (Rodriguez-Santiago et al., 2010; Do et al., 2009; Gysin et al., 2007; Tosic et al., 2006) and are related with decreased GSH levels in the cerebrospinal fluid, prefrontal cortex and post-mortem caudate of patients (Do…”
BackgroundInteraction between the catalytic and modifier subunits of glutamate-cysteine ligase
Yang, Y., Chen, Y., Johansson, E., Schneider, S. N., Shertzer, H. G., Nebert, D. W., & Dalton, T. P. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.02.003 · Cited by 40
Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential
Dwir, D., Khadimallah, I., Xin, L., Rahman, M., Du, F., Öngür, D., & Kim, Q. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad012 · Cited by 46
“As discussed above, GSH has been implicated in SZ pathophysiology; certain key GSH gene polymorphisms have functional consequences (Tosic et al., 2006; Gysin et al., 2007) that lead to low brain GSH in high-risk genotypes (Xin et al., 2016).”
BackgroundNeurobiology of Schizophrenia Onset
Woo, T.-U. W. (2013) · Current topics in behavioral neurosciences · doi:10.1007/7854_2013_243 · Cited by 49
“Protein and mRNA expression of the catalytic subunit of GCL, GCLC, also appear to be decreased under baseline conditions as well as under oxidative stress (Tosic et al. 2006; Gysin et al. 2007).”
BackgroundFöller, M., Harris, I. S., Elia, A., John, R., Lang, F. J. W., Kavanagh, T. J., & Mak, T. W. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.70 · Cited by 41
Olsen, L., Hansen, T. F., Jakobsen, K. D., Djurovic, S., Melle, I. S., Agartz, I., Hall, H., Ullum, H., Timm, S., Wang, A. G., et al. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-39 · Cited by 47
“Interestingly, oxidative stress itself has recently been linked to schizophrenia[ 43 ] possibly hinting at a diseasesusceptible regulatory network in the brain.”
BackgroundSelf-citationMatsuzawa, D., Hashimoto, K., Hashimoto, T., Shimizu, E., Watanabe, H., Fujita, Y., & Iyo, M. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30776 · Cited by 37
“Case–control association studies between GSTM1 [Harada et al., 2001; Pae et al., 2004], GSTP1 [Pae et al., 2003; Shinkai et al., 2005], GPX1 [Shinkai et al., 2004], and GCLM [Tosic et al., 2006] and schizophrenia have been reported.”
BackgroundMethodInfluentialCao, B., Jin, M., Brietzke, E. M., McIntyre, R. S., Wang, D., Rosenblat, J. D., Ragguett, R., Zhang, C., Sun, X., Rong, C., et al. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12779 · Cited by 40
“It is a limiting substrate for antioxidant glutathione synthesis, an essential product for oxidative stress and immunoregulation.(57) In contrast with the results of previous studies,(19) our study found that Lcysteine and glutamic acid were positively correlated with TG and VLDL; thus, with the pathway analysis we hy…”
Result
Metadata
- Authors
- Tosic, M., Ott, J., Barral, S., Bovet, P., Deppen, P., Gheorghita, F., Matthey, M.-L., Parnas, J., Preisig, M., Saraga, M., Solida, A., Timm, S., Wang, A. G., Werge, T., Cuénod, M., & Quang Do, K.
- Affiliations
- Rockefeller University (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Hvidovre Hospital (DK)
- Frederiksberg Hospital (DK)
- Amager Hospital (DK)
- Sankt Hans Hospital (DK)
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 79
- Issue
- 3
- Pages
- 586-592
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1559555
- OpenAlex
- W2039366241
- Cited by
- 234
- References
- 43
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 6 · 2023: 12 · 2022: 5 · 2021: 10 · 2020: 6 · 2019: 9 · 2018: 6 · 2017: 16 · 2016: 12 · 2015: 8 · 2014: 21 · 2013: 10 · 2012: 15
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2513 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R01MH044292, MH 44292, R37MH044292)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Keywords
- schizophrenia, oxidative stress, GCLM, glutathione metabolism, glutathione, genetic susceptibility, redox regulation, cerebrospinal fluid, prefrontal cortex, fibroblast gene expression
- MeSH terms
- Fibroblasts, Glutamate-Cysteine Ligase, Gene Frequency, Glutathione, Humans, RNA, Messenger, Schizophrenia, Down-Regulation, Case-Control Studies, Oxidative Stress, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.